Glaxo Sued For False Advertising Of Avandia

June 3, 2010 by admin  
Filed under News Stories

June 3, 2010

Natural News

By Ethan A. Huff

(NaturalNews) Recent reports revealing the dangers of GlaxoSmithKline’s (GSK) diabetes drug, Avandia, have not gone unnoticed. Santa Clara County in Northern California recently filed a lawsuit against the drug giant for suppressing evidence that the drug increases heart attack risk.

The lawsuit is demanding that every person in California who has taken Avandia receive restitution from GSK. California state law prohibits companies from falsely advertising their products, and according to Santa Clara County, GSK did just this with its Avandia drug.

“GSK’s unlawful conduct has cost patients, their insurers and government payers millions of dollars, and it has caused needless suffering to thousands of Californians,” explained Miguel Marquez, Santa Clara County’s acting county counsel. “This is precisely the sort of corporate malfeasance that California law prohibits.”

Click here for the full report.

And You Thought a Prescription Was Private

August 10, 2009 by admin  
Filed under News Stories

August 9, 2009

New York Times

By Milt Freudenheim

More than 10 years after she tried without success to have a baby, Marcy Campbell Krinsk is still receiving painful reminders in her mail. The ads and promotions started after she bought fertility drugs at a pharmacy in San Diego.

Marketers got hold of her name, and she found coupons and samples in her mail that shadowed the growth of an imaginary child — at first, for Pampers and baby formula, then for discounts on family photos, and all the way through the years to gifts suitable for an elementary school graduate.

“I had three different in vitro procedures,” said Ms. Krinsk, now 55, a former telecommunications executive who lives with her husband in San Diego. “To just go to the mailbox and get that stuff, time after time after time, it was just awful.”

Like many other people, Ms. Krinsk thought that her prescription information was private. But in fact, prescriptions, and all the information on them — including not only the name and dosage of the drug and the name and address of the doctor, but also the patient’s address and Social Security number — are a commodity bought and sold in a murky marketplace, often without the patients’ knowledge or permission.

That may change if some little-noted protections from the Obama administration are strictly enforced. The federal stimulus law enacted in February prohibits in most cases the sale of personal health information, with a few exceptions for research and public health measures like tracking flu epidemics. It also tightens rules for telling patients when hackers or health care workers have stolen their Social Security numbers or medical information, as happened to Britney Spears, Maria Shriver and Farrah Fawcett before she died in June.

“The new rules will plug some gaping holes in our federal health privacy laws,” said Deven McGraw, a health privacy expert at the nonprofit Center for Democracy and Technology in Washington. “For the first time, pharmacy benefit managers that handle most prescriptions and banks and contractors that process millions of medical claims will be held accountable for complying with federal privacy and security rules.”

The law won’t shut down the medical data mining industry, but there will be more restrictions on using private information without patients’ consent and penalties for civil violations will be increased. Government agencies are still writing new regulations called for in the law.

Ms. Krinsk was never able to find out who sold her information, but companies that have been accused in lawsuits of buying and selling personal medical data include drugstore chains like Walgreens and data-mining companies like IMS Health and Verispan. CVS Caremark, which handles prescriptions for corporate clients, has also been accused of violating patients’ privacy.

These companies all say that names of patients are removed or encrypted before data is sold, typically to drug manufacturers.

But as Ms. Krinsk’s case shows, there are leaks in the system.

Before the changes, privacy regulations mainly applied to hospitals and doctors. Enforcement was weak, and there were lots of loopholes.

Privacy experts cite research by Latanya Sweeney, director of the Data Privacy Lab at Carnegie Mellon University in Pittsburgh, which shows that a computer-savvy snooper can easily match names, addresses, Social Security numbers and so on to “re-identify” information that had supposedly been rendered anonymous.

“Our biggest concern is the complete lack of protection against re-identifying data that was supposed to be anonymous and secure,” Ms. McGraw said.

Tracking prescriptions has been a big business for decades. Data miners say their research is valuable because gathering and analyzing information from thousands of people helps identify trends and provides indications of potentially dangerous side effects of drugs.

Click here to continue reading at the New York  Times